14. Referanser

Abida, W., Cheng, M. L., Armenia, J., Middha, S., Autio, K. A., Vargas, H. A., Rathkopf, D., Morris, M. J., ... Scher, H. I. (2019). Analysis of the Prevalence of Microsatellite Instability in Prostate Cancer and Response to Immune Checkpoint Blockade. JAMA oncology, 5(4), 471-478.

Agarwal, N., Azad, A., Carles, J., Fay, A. P., Matsubara, N., Szczylik, C., Giorgi, U. D., Joung, J. Y., ... Fizazi, K. (2025). Final overall survival (OS) with talazoparib (TALA) + enzalutamide (ENZA) as first-line treatment in unselected patients with metastatic castration-resistant prostate cancer (mCRPC) in the phase 3 TALAPRO-2 trial. Journal of Clinical Oncology, 43(5 suppl), LBA18.

Aksnessæther, B. Y., Lund, J., Myklebust, T., Klepp, O. H., Skovlund, E., Roth Hoff, S., & Solberg, A. (2019). Second cancers in radically treated Norwegian prostate cancer patients. Acta Oncologica, 58(6), 838-844.

Albertsen, P. C., Hanley, J. A., Gleason, D. F., & Barry, M. J. (1998). Competing risk analysis of men aged 55 to 74 years at diagnosis managed conservatively for clinically localized prostate cancer. JAMA, 280(11), 975-80.

Ali, A., Hoyle, A., Haran Á, M., Brawley, C. D., Cook, A., Amos, C., Calvert, J., Douis, H., ... Clarke, N. W. (2021). Association of Bone Metastatic Burden With Survival Benefit From Prostate Radiotherapy in Patients With Newly Diagnosed Metastatic Prostate Cancer: A Secondary Analysis of a Randomized Clinical Trial. JAMA oncology, 7(4), 555-563.

Andreyev, H. J., Wotherspoon, A., Denham, J. W., & Hauer-Jensen, M. (2010). Defining pelvic-radiation disease for the survivorship era. Lancet Oncology, 11(4), 310-2.

Association of the Nordic Cancer Registries (2023). NORDCAN – Kreftstatistikk for de nordiske landene. Version 9.3. [database]. [s.l.]: Association of the Nordic Cancer Registries. Danish Cancer Society. Hentet 25. juni 2024 fra http://www-dep.iarc.fr/nordcan.htm

Attard, G., Murphy, L., Clarke, N. W., Cross, W., Jones, R. J., Parker, C. C., Gillessen, S., Cook, A., ... James, N. D. (2022). Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol. Lancet, 399(10323), 447-460.

Bernard, J. R. ,. J., Buskirk, S. J., Heckman, M. G., Diehl, N. N., Ko, S. J., Macdonald, O. K., Schild, S. E., & Pisansky, T. M. (2010). Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis. International Journal of Radiation Oncology, Biology, Physics, 76(3), 735-40.

Bolla, M., de Reijke, T. M., Van Tienhoven, G., Van den Bergh, A. C., Oddens, J., Poortmans, P. M., Gez, E., Kil, P., ... Collette, L. (2009). Duration of androgen suppression in the treatment of prostate cancer. New England Journal of Medicine, 360(24), 2516-27.

Bray, F., Lortet-Tieulent, J., Ferlay, J., Forman, D., & Auvinen, A. (2010). Prostate cancer incidence and mortality trends in 37 European countries: an overview. European Journal of Cancer, 46(17), 3040-52.

Brierley, J. D. ,., Gospodarowicz, M. K., Wittekind, C. (2017). TNM classification of malignant tumors. John Wiley & Sons, Inc.

Bøhn, S. H., Fosså, S. D., Wisløff, T., & Thorsen, L. (2019). Physical activity and associations with treatment-induced adverse effects among prostate cancer patients. Supportive Care in Cancer, 27(3), 1001-1011.

Carter, H. B., Helfand, B., Mamawala, M., Wu, Y., Landis, P., Yu, H., Wiley, K., Na, R., ... Xu, J. (2019). Germline Mutations in ATM and BRCA1/2 Are Associated with Grade Reclassification in Men on Active Surveillance for Prostate Cancer. European Urology, 75(5), 743-749.

Castro, E., Goh, C., Olmos, D., Saunders, E., Leongamornlert, D., Tymrakiewicz, M., Mahmud, N., Dadaev, T., ... Eeles, R. (2013). Germline BRCA mutations are associated with higher risk of nodal involvement, distant metastasis, and poor survival outcomes in prostate cancer. Journal of Clinical Oncology, 31(14), 1748-57.

Catton, C. N., Lukka, H., Gu, C. S., Martin, J. M., Supiot, S., Chung, P. W. M., Bauman, G. S., Bahary, J. P., ... Levine, M. N. (2017). Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer. Journal of Clinical Oncology, 35(17), 1884-1890.

Center, M. M., Jemal, A., Lortet-Tieulent, J., Ward, E., Ferlay, J., Brawley, O., & Bray, F. (2012). International variation in prostate cancer incidence and mortality rates. European Urology, 61(6), 1079-92.

Chen, H., Ewing, C. M., Zheng, S., Grindedaal, E. M., Cooney, K. A., Wiley, K., Djurovic, S., Andreassen, O. A., ... Isaacs, W. B. (2018). Genetic factors influencing prostate cancer risk in Norwegian men. Prostate, 78(3), 186-192.

Cook, L. S., Goldoft, M., Schwartz, S. M., & Weiss, N. S. (1999). Incidence of adenocarcinoma of the prostate in Asian immigrants to the United States and their descendants. Journal of Urology, 161(1), 152-5.

Cornford, P., Bellmunt, J., Bolla, M., Briers, E., De Santis, M., Gross, T., Henry, A. M., Joniau, S., ... Mottet, N. (2017). EAU-ESTRO-SIOG Guidelines on Prostate Cancer. Part II: Treatment of Relapsing, Metastatic, and Castration-Resistant Prostate Cancer. European Urology, 71(4), 630-642.

Cornford, P., Tilki, D., van den Bergh, R. C. N., Eberli, D., De Meerleer, G., De Santis, M., ... Gillessen, S. (2025). EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer (rev. utg.) Arnhem: European Association of Urology.

Cornford, P., Tilki, D., van den Bergh, R. C. N., Eberli, D., De Meerleer, G., De Santis, M., ... Gillessen, S. (2025). Diagnostic evaluation. I: EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer (rev. utg.) Arnhem: European Association of Urology. Hentet fra https://uroweb.org/guidelines/prostate-cancer/chapter/diagnostic-evaluation

Cornford, P. . D., van den Bergh, R. C. N., Briers, E., Patient Advocate (European Prostate Cancer Coalition/Europa UOMO), Eberli, D., De Meerleer, G., ... De Santis, M. (2024). EAU - EANM - ESTRO - ESUR - ISUP - SIOG Guidelines on Prostate Cancer (rev. utg.) Arnhem: European Association of Urology.

D'Amico, A. V., Chen, M. H., Renshaw, A. A., Loffredo, M., & Kantoff, P. W. (2008). Androgen suppression and radiation vs radiation alone for prostate cancer: a randomized trial. JAMA, 299(3), 289-95.

Dal Pra, A., Dirix, P., Khoo, V., Carrie, C., Cozzarini, C., Fonteyne, V., Ghadjar, P., Gomez-Iturriaga, A., ... Wiegel, T. (2023). ESTRO ACROP guideline on prostate bed delineation for postoperative radiotherapy in prostate cancer. Clinical and translational radiation oncology, 41, 100638.

De Meerleer, G., Berghen, C., Briganti, A., Vulsteke, C., Murray, J., Joniau, S., Leliveld, A. M., Cozzarini, C., ... Bossi, A. (2021). Elective nodal radiotherapy in prostate cancer. Lancet Oncology, 22(8), e348-e357.

Donovan, J. L., Hamdy, F. C., Lane, J. A., Young, G. J., Metcalfe, C., Walsh, E. I., Davis, M., Steuart-Feilding, T., ... Neal, D. E. (2023). Patient-Reported Outcomes 12 Years after Localized Prostate Cancer Treatment. NEJM evidence, 2(4), EVIDoa2300018.

Droz, J. P., Aapro, M., Balducci, L., Boyle, H., Van den Broeck, T., Cathcart, P., Dickinson, L., Efstathiou, E., ... Sugihara, T. (2014). Management of prostate cancer in older patients: updated recommendations of a working group of the International Society of Geriatric Oncology. Lancet Oncology, 15(9), e404-14.

Edwards, S. M., Evans, D. G., Hope, Q., Norman, A. R., Barbachano, Y., Bullock, S., Kote-Jarai, Z., Meitz, J., ... Eeles, R. A. (2010). Prostate cancer in BRCA2 germline mutation carriers is associated with poorer prognosis. British Journal of Cancer, 103(6), 918-24.

Edwards, S. M., Kote-Jarai, Z., Meitz, J., Hamoudi, R., Hope, Q., Osin, P., Jackson, R., Southgate, C., ... Eeles, R. A. (2003). Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. American Journal of Human Genetics, 72(1), 1-12.

Eisenberger, M., Hardy-Bessard, A. C., Kim, C. S., Géczi, L., Ford, D., Mourey, L., Carles, J., Parente, P., ... de Bono, J. (2017). Phase III Study Comparing a Reduced Dose of Cabazitaxel (20 mg/m(2)) and the Currently Approved Dose (25 mg/m(2)) in Postdocetaxel Patients With Metastatic Castration-Resistant Prostate Cancer-PROSELICA. Journal of Clinical Oncology, 35(28), 3198-3206.

Epstein, J. I., Amin, M. B., Reuter, V. E., & Humphrey, P. A. (2017). Contemporary Gleason Grading of Prostatic Carcinoma: An Update With Discussion on Practical Issues to Implement the 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 41(4), e1-e7.

Epstein, J. I., Egevad, L., Amin, M. B., Delahunt, B., Srigley, J. R., & Humphrey, P. A. (2016). The 2014 International Society of Urological Pathology (ISUP) Consensus Conference on Gleason Grading of Prostatic Carcinoma: Definition of Grading Patterns and Proposal for a New Grading System. American Journal of Surgical Pathology, 40(2), 244-52.

Epstein, J. I., & Kryvenko, O. N. (2021). A Comparison of Genitourinary Society Pathology and International Society of Urological Pathology Prostate Cancer Guidelines. European Urology, 79(1), 3-5.

European Commission (2022). Council Recommendation of 9 December 2022 on strengthening prevention through early detection: A new EU approach on cancer screening replacing Council Recommendation 2003/878/EC (Official Journal of the European Union C 473/1). Hentet fra https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=CELEX%3A32022H1213%2801%29

Ewing, C. M., Ray, A. M., Lange, E. M., Zuhlke, K. A., Robbins, C. M., Tembe, W. D., Wiley, K. E., Isaacs, S. D., ... Cooney, K. A. (2012). Germline mutations in HOXB13 and prostate-cancer risk. New England Journal of Medicine, 366(2), 141-9.

Fanti, S., Goffin, K., Hadaschik, B. A., Herrmann, K., Maurer, T., MacLennan, S., Oprea-Lager, D. E., Oyen, W. J., ... Bjartell, A. (2021). Consensus statements on PSMA PET/CT response assessment criteria in prostate cancer. European Journal of Nuclear Medicine and Molecular Imaging, 48(2), 469-476.

Filimonova, I., Schmidt, D., Mansoorian, S., Weissmann, T., Siavooshhaghighi, H., Cavallaro, A., Kuwert, T., Bert, C., ... Putz, F. (2020). The Distribution of Pelvic Nodal Metastases in Prostate Cancer Reveals Potential to Advance and Personalize Pelvic Radiotherapy. Frontiers in Oncology, 10, 590722.

Fizazi, K., Carducci, M., Smith, M., Damião, R., Brown, J., Karsh, L., Milecki, P., Shore, N., ... Goessl, C. (2011). Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study. Lancet, 377(9768), 813-22.

Fizazi, K., Foulon, S., Carles, J., Roubaud, G., McDermott, R., Fléchon, A., Tombal, B., Supiot, S., ... Bossi, A. (2022). Abiraterone plus prednisone added to androgen deprivation therapy and docetaxel in de novo metastatic castration-sensitive prostate cancer (PEACE-1): a multicentre, open-label, randomised, phase 3 study with a 2 × 2 factorial design. Lancet, 399(10336), 1695-1707.

Fizazi, K., Shore, N. D., Tammela, T., Ulys, A., Vjaters, E., Polyakov, S., Jievaltas, M., Luz, M., ... Smith, M. R. (2020). Overall survival (OS) results of phase III ARAMIS study of darolutamide (DARO) added to androgen deprivation therapy (ADT) for nonmetastatic castration-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology, 38(15_suppl), 5514.

Fossati, N., Willemse, P. M., Van den Broeck, T., van den Bergh, R. C. N., Yuan, C. Y., Briers, E., Bellmunt, J., Bolla, M., ... Joniau, S. (2017). The Benefits and Harms of Different Extents of Lymph Node Dissection During Radical Prostatectomy for Prostate Cancer: A Systematic Review. European Urology, 72(1), 84-109.

Frånlund, M., Månsson, M., Godtman, R. A., Aus, G., Holmberg, E., Kollberg, K. S., Lodding, P., Pihl, C. G., ... Hugosson, J. (2022). Results from 22 years of Followup in the Göteborg Randomized Population-Based Prostate Cancer Screening Trial. Journal of Urology, 208(2), 292-300.

Gandaglia, G., Trinh, Q. D., Hu, J. C., Schiffmann, J., Becker, A., Roghmann, F., Popa, I., Tian, Z., ... Abdollah, F. (2014). The impact of robot-assisted radical prostatectomy on the use and extent of pelvic lymph node dissection in the "post-dissemination" period. European Journal of Surgical Oncology, 40(9), 1080-6.

Gaustad, J. V., Smedslund, G., Hestevik, C. H., Risstad, H., Hagen, G., Harboe, I., ... Hamidi, V. (2024). Robotassistert prostatektomi ved prostatakreft: En metodevurdering Oslo: Folkehelseinstituttet. Hentet fra https://www.fhi.no/publ/2024/robotassistert-prostatektomi-ved-prostatakreft/

Gillessen, S., Choudhury, A., Saad, F., Gallardo, E., Soares, A., Loriot, Y., McDermott, R. S., Rodriguez-Vida, A., ... Tombal, B. (2024). LBA1 A randomized multicenter open label phase III trial comparing enzalutamide vs a combination of Radium-223 (Ra223) and enzalutamide in asymptomatic or mildly symptomatic patients with bone metastatic castration-resistant prostate cancer (mCRPC): First results of EORTC-GUCG 1333/PEACE-3. Annals of Oncology, 35(Suppl 2), S1254.

Gillessen, S., Tombal, B., Turco, F., Choudhury, A., Rodriguez-Vida, A., Gallardo, E., Velho, P. I., Nolè, F., ... Saad, F. (2025). Decrease in Fracture Rate with Mandatory Bone-protecting Agents in the EORTC 1333/PEACE-3 Trial Comparing Radium-223 Combined with Enzalutamide Versus Enzalutamide Alone: A Safety Analysis. European Urology, 87(3), 285-288.

Gjerset, G. M., Kiserud, C. E., Loge, J. H., Fosså, S. D., Wisløff, T., Gudbergsson, S. B., Oldervoll, L. M., & Thorsen, L. (2019). Changes in fatigue, health-related quality of life and physical activity after a one-week educational program for cancer survivors. Acta Oncologica, 58(5), 682-689.

Grindedal, E. M., Møller, P., Eeles, R., Stormorken, A. T., Bowitz-Lothe, I. M., Landrø, S. M., Clark, N., Kvåle, R., ... Maehle, L. (2009). Germ-line mutations in mismatch repair genes associated with prostate cancer. Cancer Epidemiology, Biomarkers and Prevention, 18(9), 2460-7.

Grindedal, E. M., Zucknick, M., Stormorken, A., Rønne, E., Tandstad, N. M., Isaacs, W. B., Axcrona, K., & Mæhle, L. (2024). Outcomes of 10 years of PSA screening for prostate cancer in Norwegian men with Lynch syndrome. The Prostate, 84(10), 945-953.

Hall, W. A., Paulson, E., Davis, B. J., Spratt, D. E., Morgan, T. M., Dearnaley, D., Tree, A. C., Efstathiou, J. A., ... Lawton, C. A. F. (2021). NRG Oncology Updated International Consensus Atlas on Pelvic Lymph Node Volumes for Intact and Postoperative Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics, 109(1), 174-185.

Hamdy, F. C., Donovan, J. L., Lane, J. A., Mason, M., Metcalfe, C., Holding, P., Davis, M., Peters, T. J., ... Neal, D. E. (2016). 10-Year Outcomes after Monitoring, Surgery, or Radiotherapy for Localized Prostate Cancer. New England Journal of Medicine, 375(15), 1415-1424.

Haque, R., UlcickasYood, M., Xu, X., Cassidy-Bushrow, A. E., Tsai, H. T., Keating, N. L., Van Den Eeden, S. K., & Potosky, A. L. (2017). Cardiovascular disease risk and androgen deprivation therapy in patients with localised prostate cancer: a prospective cohort study. British Journal of Cancer, 117(8), 1233-1240.

Helsedirektoratet (17. desember 2021). Endokarditt, profylakse ved inngrep. I: Antibiotika i sykehus. [nettdokument]. Oslo: Helsedirektoratet. Hentet 03. juli 2024 fra https://www.helsedirektoratet.no/retningslinjer/antibiotika-i-sykehus/endokarditt/endokarditt-profylakse-ved-inngrep

Himelstein, A. L., Foster, J. C., Khatcheressian, J. L., Roberts, J. D., Seisler, D. K., Novotny, P. J., Qin, R., Go, R. S., ... Shapiro, C. L. (2017). Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases: A Randomized Clinical Trial. JAMA, 317(1), 48-58.

Honoré, A., Moen, C. A., Juliebø-Jones, P., Reisaeter, L. A. R., Gravdal, K., Chaudhry, A. A., Rawal, R., Sandøy, A., & Beisland, C. (2024). Transitioning from transrectal to transperineal prostate biopsy using a freehand cognitive approach. BJU International, 133(3), 324-331.

Hugosson, J., Roobol, M. J., Månsson, M., Tammela, T. L. J., Zappa, M., Nelen, V., Kwiatkowski, M., Lujan, M., ... Auvinen, A. (2019). A 16-yr Follow-up of the European Randomized study of Screening for Prostate Cancer. European Urology, 76(1), 43-51.

Hussain, M., Tombal, B., Saad, F., Fizazi, K., Sternberg, C. N., Crawford, E. D., Shore, N., Kopyltsov, E., ... Smith, M. R. (2023). Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial. Journal of Clinical Oncology, 41(20), 3595-3607.

Ilic, D., O'Connor, D., Green, S., & Wilt, T. J. (2011). Screening for prostate cancer: an updated Cochrane systematic review. BJU International, 107(6), 882-91.

Jacewicz, M., Günzel, K., Rud, E., Sandbæk, G., Magheli, A., Busch, J., Hinz, S., & Baco, E. (2022). Antibiotic prophylaxis versus no antibiotic prophylaxis in transperineal prostate biopsies (NORAPP): a randomised, open-label, non-inferiority trial. Lancet Infectious Diseases, 22(10), 1465-1471.

James, N. D., Clarke, N. W., Cook, A., Ali, A., Hoyle, A. P., Attard, G., Brawley, C. D., Chowdhury, S., ... Sydes, M. R. (2022). Abiraterone acetate plus prednisolone for metastatic patients starting hormone therapy: 5-year follow-up results from the STAMPEDE randomised trial (NCT00268476). International Journal of Cancer, 151(3), 422-434.

James, N. D., Spears, M. R., Clarke, N. W., Dearnaley, D. P., Mason, M. D., Parker, C. C., Ritchie, A. W., Russell, J. M., ... Sydes, M. R. (2016). Failure-Free Survival and Radiotherapy in Patients With Newly Diagnosed Nonmetastatic Prostate Cancer: Data From Patients in the Control Arm of the STAMPEDE Trial. JAMA oncology, 2(3), 348-57.

Joseph, D., Denham, J. W., Steigler, A., Lamb, D. S., Spry, N. A., Stanley, J., Shannon, T., Duchesne, G., ... Attia, J. (2020). Radiation Dose Escalation or Longer Androgen Suppression to Prevent Distant Progression in Men With Locally Advanced Prostate Cancer: 10-Year Data From the TROG 03.04 RADAR Trial. International Journal of Radiation Oncology, Biology, Physics, 106(4), 693-702.

Karlsson, R., Aly, M., Clements, M., Zheng, L., Adolfsson, J., Xu, J., Grönberg, H., & Wiklund, F. (2014). A population-based assessment of germline HOXB13 G84E mutation and prostate cancer risk. European Urology, 65(1), 169-76.

Keating, N. L., O'Malley, A. J., & Smith, M. R. (2006). Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer. Journal of Clinical Oncology, 24(27), 4448-56.

Kellokumpu-Lehtinen, P. L., Harmenberg, U., Joensuu, T., McDermott, R., Hervonen, P., Ginman, C., Luukkaa, M., Nyandoto, P., ... Joensuu, H. (2013). 2-Weekly versus 3-weekly docetaxel to treat castration-resistant advanced prostate cancer: a randomised, phase 3 trial. Lancet Oncology, 14(2), 117-24.

Kerkmeijer, L. G. W., Groen, V. H., Pos, F. J., Haustermans, K., Monninkhof, E. M., Smeenk, R. J., Kunze-Busch, M., de Boer, J. C. J., ... van der Heide, U. A. (2021). Focal Boost to the Intraprostatic Tumor in External Beam Radiotherapy for Patients With Localized Prostate Cancer: Results From the FLAME Randomized Phase III Trial. Journal of Clinical Oncology, 39(7), 787-796.

Kishan, A. U., Cook, R. R., Ciezki, J. P., Ross, A. E., Pomerantz, M. M., Nguyen, P. L., Shaikh, T., Tran, P. T., ... King, C. R. (2018). Radical Prostatectomy, External Beam Radiotherapy, or External Beam Radiotherapy With Brachytherapy Boost and Disease Progression and Mortality in Patients With Gleason Score 9-10 Prostate Cancer. JAMA, 319(9), 896-905.

Kneebone, A., Fraser-Browne, C., Duchesne, G. M., Fisher, R., Frydenberg, M., Herschtal, A., Williams, S. G., Brown, C., ... Pearse, M. (2020). Adjuvant radiotherapy versus early salvage radiotherapy following radical prostatectomy (TROG 08.03/ANZUP RAVES): a randomised, controlled, phase 3, non-inferiority trial. The Lancet. Oncology, 21(10), 1331-1340.

Kote-Jarai, Z., Olama, A. A., Giles, G. G., Severi, G., Schleutker, J., Weischer, M., Campa, D., Riboli, E., ... Eeles, R. A. (2011). Seven prostate cancer susceptibility loci identified by a multi-stage genome-wide association study. Nature Genetics, 43(8), 785-91.

Kumar, S., Shelley, M., Harrison, C., Coles, B., Wilt, T. J., & Mason, M. D. (2006). Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer. Cochrane Database of Systematic Reviews, 2006(4), Cd006019.

Kvåle, R., Myklebust, T., Engholm, G., Heinävaara, S., Wist, E., & Møller, B. (2017). Prostate and breast cancer in four Nordic countries: A comparison of incidence and mortality trends across countries and age groups 1975-2013. International Journal of Cancer, 141(11), 2228-2242.

Kyrdalen, A. E., Dahl, A. A., Hernes, E., Cvancarova, M., & Fosså, S. D. (2010). Fatigue in hormone-naïve prostate cancer patients treated with radical prostatectomy or definitive radiotherapy. Prostate Cancer and Prostatic Diseases, 13(2), 144-50.

Larsen, I. K. (2024). Cancer in Norway 2023: cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway.

Larsen, I. K. (2025). Cancer in Norway 2024: cancer incidence, mortality, survival and prevalence in Norway. Cancer Registry of Norway.

Lawton, C. A., Winter, K., Grignon, D., & Pilepich, M. V. (2005). Androgen suppression plus radiation versus radiation alone for patients with stage D1/pathologic node-positive adenocarcinoma of the prostate: updated results based on national prospective randomized trial Radiation Therapy Oncology Group 85-31. Journal of Clinical Oncology, 23(4), 800-7.

Li, S., Silvestri, V., Leslie, G., Rebbeck, T. R., Neuhausen, S. L., Hopper, J. L., Nielsen, H. R., Lee, A., ... Antoniou, A. C. (2022). Cancer Risks Associated With BRCA1 and BRCA2 Pathogenic Variants. Journal of Clinical Oncology, 40(14), 1529-1541.

Löffeler, S., Bertilsson, H., Müller, C., Aas, K., Haugnes, H. S., Aksnessæther, B., Pesonen, M., Thon, K., ... Brasso, K. (2024). Protocol of a randomised, controlled trial comparing immediate curative therapy with conservative treatment in men aged ≥75 years with non-metastatic high-risk prostate cancer (SPCG 19/GRand-P). BJU International, 133(6), 680-689.

Lorente, D., Omlin, A., Ferraldeschi, R., Pezaro, C., Perez, R., Mateo, J., Altavilla, A., Zafeirou, Z., ... Attard, G. (2014). Tumour responses following a steroid switch from prednisone to dexamethasone in castration-resistant prostate cancer patients progressing on abiraterone. British Journal of Cancer, 111(12), 2248-53.

MacInnis, R. J., Severi, G., Baglietto, L., Dowty, J. G., Jenkins, M. A., Southey, M. C., Hopper, J. L., & Giles, G. G. (2013). Population-based estimate of prostate cancer risk for carriers of the HOXB13 missense mutation G84E. PloS One, 8(2), e54727.

Martin, R. M., Vatten, L., Gunnell, D., Romundstad, P., & Nilsen, T. I. (2008). Lower urinary tract symptoms and risk of prostate cancer: the HUNT 2 Cohort, Norway. International Journal of Cancer, 123(8), 1924-8.

Mehralivand, S., Shih, J. H., Harmon, S., Smith, C., Bloom, J., Czarniecki, M., Gold, S., Hale, G., ... Turkbey, B. (2019). A Grading System for the Assessment of Risk of Extraprostatic Extension of Prostate Cancer at Multiparametric MRI. Radiology, 290(3), 709-719.

Moch, H., Humphrey, P. A., Ulbright, T. M. (2016). WHO Classification of Tumours of the Urinary System and Male Genital Organs (4 utg.) (WHO Classification of Tumours, Volume 8). Lyon: International Agency for Research on Cancer.

Morris, W. J., Tyldesley, S., Rodda, S., Halperin, R., Pai, H., McKenzie, M., Duncan, G., Morton, G., ... Murray, N. (2017). Androgen Suppression Combined with Elective Nodal and Dose Escalated Radiation Therapy (the ASCENDE-RT Trial): An Analysis of Survival Endpoints for a Randomized Trial Comparing a Low-Dose-Rate Brachytherapy Boost to a Dose-Escalated External Beam Boost for High- and Intermediate-risk Prostate Cancer. International Journal of Radiation Oncology, Biology, Physics, 98(2), 275-285.

Mosele, F., Remon, J., Mateo, J., Westphalen, C. B., Barlesi, F., Lolkema, M. P., Normanno, N., Scarpa, A., ... André, F. (2020). Recommendations for the use of next-generation sequencing (NGS) for patients with metastatic cancers: a report from the ESMO Precision Medicine Working Group. Annals of Oncology, 31(11), 1491-1505.

Mottet, N., Cornford, P., van den Bergh, R. C. N., Briers, E., Santis, M. D., Fanti, S., ... Gillessen, S. (2020). EAU - EANM - ESTRO - ESUR - SIOG Guidelines on Prostate Cancer (rev. utg.) Arnhem: European Association of Urology.

Murthy, V., Maitre, P., Kannan, S., Panigrahi, G., Krishnatry, R., Bakshi, G., Prakash, G., Pal, M., ... Mahantshetty, U. (2021). Prostate-Only Versus Whole-Pelvic Radiation Therapy in High-Risk and Very High-Risk Prostate Cancer (POP-RT): Outcomes From Phase III Randomized Controlled Trial. Journal of Clinical Oncology, 39(11), 1234-1242.

Nasjonalt kvalitetsregister for prostatakreft (2017). Årsrapport 2016 med resultater og forbedringstiltak Oslo: Kreftregisteret. Hentet fra https://www.fhi.no/globalassets/publikasjoner-og-rapporter/arsrapporter/publisert-2017/arsrapport-2016_prostatakreft.pdf

Nasjonalt kvalitetsregister for prostatakreft (2024). Årsrapport 2021; Resultater og forbedringstiltak fra Nasjonalt kvalitetsregister for prostatakreft Oslo: Kreftregisteret. Hentet fra https://www.kvalitetsregistre.no/sites/default/files/2022-06/%C3%85rsrapport%202021%20Nasjonalt%20kvalitetsregister%20for%20prostatakreft.pdf

Nyberg, T., Frost, D., Barrowdale, D., Evans, D. G., Bancroft, E., Adlard, J., Ahmed, M., Barwell, J., ... Antoniou, A. C. (2020). Prostate Cancer Risks for Male BRCA1 and BRCA2 Mutation Carriers: A Prospective Cohort Study. European Urology, 77(1), 24-35.

Odisho, A. Y., Washington, S. L. ,. 3., Meng, M. V., Cowan, J. E., Simko, J. P., & Carroll, P. R. (2013). Benign prostate glandular tissue at radical prostatectomy surgical margins. Urology, 82(1), 154-9.

Oldenburger, E., Brown, S., Willmann, J., van der Velden, J. M., van der Linden, Y. M., Kazmierska, J., Menten, J., Andratschke, N., ... Hoskin, P. (2022). ESTRO ACROP guidelines for external beam radiotherapy of patients with complicated bone metastases. Radiotherapy and Oncology, 173, 240-253.

Oudard, S., Fizazi, K., Sengeløv, L., Daugaard, G., Saad, F., Hansen, S., Hjälm-Eriksson, M., Jassem, J., ... Sartor, O. (2017). Cabazitaxel Versus Docetaxel As First-Line Therapy for Patients With Metastatic Castration-Resistant Prostate Cancer: A Randomized Phase III Trial-FIRSTANA. Journal of Clinical Oncology, 35(28), 3189-3197.

Page, E. C., Bancroft, E. K., Brook, M. N., Assel, M., Hassan Al Battat, M., Thomas, S., Taylor, N., Chamberlain, A., ... Eeles, R. A. (2019). Interim Results from the IMPACT Study: Evidence for Prostate-specific Antigen Screening in BRCA2 Mutation Carriers. European Urology, 76(6), 831-842.

Parker, C., Nilsson, S., Heinrich, D., Helle, S. I., O'Sullivan, J. M., Fosså, S. D., Chodacki, A., Wiechno, P., ... Sartor, O. (2013). Alpha emitter radium-223 and survival in metastatic prostate cancer. New England Journal of Medicine, 369(3), 213-23.

Parker, C. C., James, N. D., Brawley, C. D., Clarke, N. W., Hoyle, A. P., Ali, A., Ritchie, A. W. S., Attard, G., ... Sydes, M. R. (2018). Radiotherapy to the primary tumour for newly diagnosed, metastatic prostate cancer (STAMPEDE): a randomised controlled phase 3 trial. Lancet, 392(10162), 2353-2366.

Petersen, L. J., Nielsen, J. B., Langkilde, N. C., Petersen, A., Afshar-Oromieh, A., De Souza, N. M., De Paepe, K., Fisker, R. V., ... Zacho, H. D. (2020). (68)Ga-PSMA PET/CT compared with MRI/CT and diffusion-weighted MRI for primary lymph node staging prior to definitive radiotherapy in prostate cancer: a prospective diagnostic test accuracy study. World Journal of Urology, 38(4), 939-948.

Pfister, D., Bolla, M., Briganti, A., Carroll, P., Cozzarini, C., Joniau, S., van Poppel, H., Roach, M., ... Zelefsky, M. J. (2014). Early salvage radiotherapy following radical prostatectomy. European Urology, 65(6), 1034-43.

Pillay, B., Wootten, A. C., Crowe, H., Corcoran, N., Tran, B., Bowden, P., Crowe, J., & Costello, A. J. (2016). The impact of multidisciplinary team meetings on patient assessment, management and outcomes in oncology settings: A systematic review of the literature. Cancer Treatment Reviews, 42, 56-72.

Pollack, A., Karrison, T. G., Balogh, A. G., Gomella, L. G., Low, D. A., Bruner, D. W., Wefel, J. S., Martin, A. G., ... Sandler, H. M. (2022). The addition of androgen deprivation therapy and pelvic lymph node treatment to prostate bed salvage radiotherapy (NRG Oncology/RTOG 0534 SPPORT): an international, multicentre, randomised phase 3 trial. Lancet, 399(10338), 1886-1901.

Popiolek, M., Rider, J. R., Andrén, O., Andersson, S. O., Holmberg, L., Adami, H. O., & Johansson, J. E. (2013). Natural history of early, localized prostate cancer: a final report from three decades of follow-up. European Urology, 63(3), 428-35.

Roach, M. ,. 3., Hanks, G., Thames, H. ,. J., Schellhammer, P., Shipley, W. U., Sokol, G. H., & Sandler, H. (2006). Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. International Journal of Radiation Oncology, Biology, Physics, 65(4), 965-74.

Salembier, C., Villeirs, G., De Bari, B., Hoskin, P., Pieters, B. R., Van Vulpen, M., Khoo, V., Henry, A., ... Fonteyne, V. (2018). ESTRO ACROP consensus guideline on CT- and MRI-based target volume delineation for primary radiation therapy of localized prostate cancer. Radiotherapy and Oncology, 127(1), 49-61.

Sargos, P., Chabaud, S., Latorzeff, I., Magné, N., Benyoucef, A., Supiot, S., Pasquier, D., Abdiche, M. S., ... Richaud, P. (2020). Adjuvant radiotherapy versus early salvage radiotherapy plus short-term androgen deprivation therapy in men with localised prostate cancer after radical prostatectomy (GETUG-AFU 17): a randomised, phase 3 trial. The Lancet. Oncology, 21(10), 1341-1352.

Sartor, O., de Bono, J., Chi, K. N., Fizazi, K., Herrmann, K., Rahbar, K., Tagawa, S. T., Nordquist, L. T., ... Krause, B. J. (2021). Lutetium-177-PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. New England Journal of Medicine, 385(12), 1091-1103.

Scher, H. I., Morris, M. J., Stadler, W. M., Higano, C., Basch, E., Fizazi, K., Antonarakis, E. S., Beer, T. M., ... Armstrong, A. J. (2016). Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3. Journal of Clinical Oncology, 34(12), 1402-18.

Schröder, F. H., Hugosson, J., Roobol, M. J., Tammela, T. L., Zappa, M., Nelen, V., Kwiatkowski, M., Lujan, M., ... Auvinen, A. (2014). Screening and prostate cancer mortality: results of the European Randomised Study of Screening for Prostate Cancer (ERSPC) at 13 years of follow-up. Lancet, 384(9959), 2027-35.

Schwarzenboeck, S. M., Rauscher, I., Bluemel, C., Fendler, W. P., Rowe, S. P., Pomper, M. G., Afshar-Oromieh, A., Herrmann, K., & Eiber, M. (2017). PSMA Ligands for PET Imaging of Prostate Cancer. Journal of Nuclear Medicine, 58(10), 1545-1552.

Siegmann, A., Bottke, D., Faehndrich, J., Lohm, G., Miller, K., Bartkowiak, D., Wiegel, T., & Hinkelbein, W. (2011). Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival: results of a retrospective study. Strahlentherapie und Onkologie, 187(8), 467-72.

Small, E. J., Saad, F., Chowdhury, S., Oudard, S., Hadaschik, B. A., Graff, J. N., Olmos, D., Mainwaring, P. N., ... Smith, M. R. (2020). Final survival results from SPARTAN, a phase III study of apalutamide (APA) versus placebo (PBO) in patients (pts) with nonmetastatic castration-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology, 38(15_suppl), 5516.

Sonpavde, G., Pond, G. R., Armstrong, A. J., Galsky, M. D., Leopold, L., Wood, B. A., Wang, S. L., Paolini, J., ... Michaelson, M. D. (2014). Radiographic progression by Prostate Cancer Working Group (PCWG)-2 criteria as an intermediate endpoint for drug development in metastatic castration-resistant prostate cancer. BJU International, 114(6b), E25-e31.

Steineck, G., Bjartell, A., Hugosson, J., Axén, E., Carlsson, S., Stranne, J., Wallerstedt, A., Persson, J., ... Wiklund, P. (2015). Degree of preservation of the neurovascular bundles during radical prostatectomy and urinary continence 1 year after surgery. European Urology, 67(3), 559-68.

Stensvold, A., Dahl, A. A., Brennhovd, B., Småstuen, M. C., Fosså, S. D., Lilleby, W., Steinsvik, A., Axcrona, K., & Smeland, S. (2013). Bother problems in prostate cancer patients after curative treatment. Urologic Oncology, 31(7), 1067-78.

Sternberg, C. N., Fizazi, K., Saad, F., Shore, N. D., Giorgi, U. D., Penson, D. F., Ferreira, U., Ivashchenko, P., ... Hussain, M. H. A. (2020). Final overall survival (OS) from PROSPER: A phase III, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (nmCRPC). Journal of Clinical Oncology, 38(15_suppl), 5515.

Stish, B. J., Pisansky, T. M., Harmsen, W. S., Davis, B. J., Tzou, K. S., Choo, R., & Buskirk, S. J. (2016). Improved Metastasis-Free and Survival Outcomes With Early Salvage Radiotherapy in Men With Detectable Prostate-Specific Antigen After Prostatectomy for Prostate Cancer. Journal of Clinical Oncology, 34(32), 3864-3871.

Sweeney, C. J., Chen, Y. H., Carducci, M., Liu, G., Jarrard, D. F., Eisenberger, M., Wong, Y. N., Hahn, N., ... DiPaola, R. S. (2015). Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer. New England Journal of Medicine, 373(8), 737-46.

Syse, A., Pham, D. Q., & Keilman, N. (2016). Befolkningsframskrivinger 2016 - 2100: Dødelighet og levealder. Økonomiske analyser, (3), 25-36.

Thorsen, L., Nilsen, T. S., Raastad, T., Courneya, K. S., Skovlund, E., & Fosså, S. D. (2012). A randomized controlled trial on the effectiveness of strength training on clinical and muscle cellular outcomes in patients with prostate cancer during androgen deprivation therapy: rationale and design. BMC Cancer, 12, 123.

Tilki, D., Preisser, F., Tennstedt, P., Tober, P., Mandel, P., Schlomm, T., Steuber, T., Huland, H., ... Ahyai, S. (2017). Adjuvant radiation therapy is associated with better oncological outcome compared with salvage radiation therapy in patients with pN1 prostate cancer treated with radical prostatectomy. BJU International, 119(5), 717-723.

Tilki, D., van den Bergh, R. C. N., Briers, E., Van den Broeck, T., Brunckhorst, O., Darraugh, J., Eberli, D., De Meerleer, G., ... Cornford, P. (2024). EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer. Part II-2024 Update: Treatment of Relapsing and Metastatic Prostate Cancer. European Urology, 86(2), 164-182.

Torre, L. A., Bray, F., Siegel, R. L., Ferlay, J., Lortet-Tieulent, J., & Jemal, A. (2015). Global cancer statistics, 2012. CA: A Cancer Journal for Clinicians, 65(2), 87-108.

Toussi, A., Stewart-Merrill, S. B., Boorjian, S. A., Psutka, S. P., Thompson, R. H., Frank, I., Tollefson, M. K., Gettman, M. T., ... Karnes, R. J. (2016). Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy-What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression?. Journal of Urology, 195(6), 1754-9.

Troeschel, A. N., Hartman, T. J., Jacobs, E. J., Stevens, V. L., Gansler, T., Flanders, W. D., McCullough, L. E., & Wang, Y. (2020). Postdiagnosis Body Mass Index, Weight Change, and Mortality From Prostate Cancer, Cardiovascular Disease, and All Causes Among Survivors of Nonmetastatic Prostate Cancer. Journal of Clinical Oncology, 38(18), 2018-2027.

Vale, C. L., Fisher, D., Kneebone, A., Parker, C., Pearse, M., Richaud, P., Sargos, P., Sydes, M. R., ... Tierney, J. F. (2020). Adjuvant or early salvage radiotherapy for the treatment of localised and locally advanced prostate cancer: a prospectively planned systematic review and meta-analysis of aggregate data. Lancet, 396(10260), 1422-1431.

van Leenders, G., van der Kwast, T. H., Grignon, D. J., Evans, A. J., Kristiansen, G., Kweldam, C. F., Litjens, G., McKenney, J. K., ... Iczkowski, K. A. (2020). The 2019 International Society of Urological Pathology (ISUP) Consensus Conference on Grading of Prostatic Carcinoma. American Journal of Surgical Pathology, 44(8), e87-e99.

Venkitaraman, R., Lorente, D., Murthy, V., Thomas, K., Parker, L., Ahiabor, R., Dearnaley, D., Huddart, R., ... Parker, C. (2015). A randomised phase 2 trial of dexamethasone versus prednisolone in castration-resistant prostate cancer. European Urology, 67(4), 673-9.

Viani, G. A., Arruda, C. V., Assis Pellizzon, A. C., & De Fendi, L. I. (2021). HDR brachytherapy as monotherapy for prostate cancer: A systematic review with meta-analysis. Brachytherapy, 20(2), 307-314.

Wallerstedt, A., Tyritzis, S. I., Thorsteinsdottir, T., Carlsson, S., Stranne, J., Gustafsson, O., Hugosson, J., Bjartell, A., ... Haglind, E. (2015). Short-term results after robot-assisted laparoscopic radical prostatectomy compared to open radical prostatectomy. European Urology, 67(4), 660-70.

Walz, J., Epstein, J. I., Ganzer, R., Graefen, M., Guazzoni, G., Kaouk, J., Menon, M., Mottrie, A., ... Artibani, W. (2016). A Critical Analysis of the Current Knowledge of Surgical Anatomy of the Prostate Related to Optimisation of Cancer Control and Preservation of Continence and Erection in Candidates for Radical Prostatectomy: An Update. European Urology, 70(2), 301-11.

WHO Classification of Tumours Editorial Board (2022). Urinary and Male Genital Tumours. International Agency for Research on Cancer.

Widmark, A., Gunnlaugsson, A., Beckman, L., Thellenberg-Karlsson, C., Hoyer, M., Lagerlund, M., Kindblom, J., Ginman, C., ... Nilsson, P. (2019). Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial. Lancet, 394(10196), 385-395.

Widmark, A., Klepp, O., Solberg, A., Damber, J. E., Angelsen, A., Fransson, P., Lund, J. A., Tasdemir, I., ... Fosså, S. D. (2009). Endocrine treatment, with or without radiotherapy, in locally advanced prostate cancer (SPCG-7/SFUO-3): an open randomised phase III trial. Lancet, 373(9660), 301-8.

Win, A. K., Lindor, N. M., Young, J. P., Macrae, F. A., Young, G. P., Williamson, E., Parry, S., Goldblatt, J., ... Jenkins, M. A. (2012). Risks of primary extracolonic cancers following colorectal cancer in lynch syndrome. Journal of the National Cancer Institute, 104(18), 1363-72.

Wood, L. J., Nail, L. M., Gilster, A., Winters, K. A., & Elsea, C. R. (2006). Cancer chemotherapy-related symptoms: evidence to suggest a role for proinflammatory cytokines. Oncology Nursing Forum, 33(3), 535-42.

Østerø Í Jákupsstovu, J., & Brodersen, J. (2018). Do men with lower urinary tract symptoms have an increased risk of advanced prostate cancer?. BMJ, 361, k1202.